Regulatory Lifecycle Support
How we help with Regulatory Lifecycle Support
Our regulatory operations team partners with our clients to format, publish, and submit regulatory documents on their behalf. We will attentively project manage all regulatory communications with health authorities and maintain all regulatory dossiers (IDEs/INDs, CTAs, 510(k)s, PMAs/NDAs, BLAs, etc.) with amendments, supplements, safety reporting, and annual reports. We stay ahead of the latest technology to support compliant submissions and promote accelerating development through technology-enabled regulatory strategies.
Halloran has expertise in all aspects of Regulatory, including eCTD submissions. Our team can fully service your document preparation needs for document formatting, PDF publishing, eCTD creation, and submission through the FDA’s Electronic Submissions Gateway (ESG). Year after year Halloran processes thousands of submissions ranging from new drug applications to lifecycle submissions. Already have an eCTD publishing vendor but looking for document formatting support? Halloran’s team provides document preparation support for many of our clients including nonclinical reports and clinical study reports.
RELATED INSIGHTS
-
Success Planning for an Original NDA / BLA Submission
This comprehensive webinar offers an insightful exploration into the intricate landscape of New Drug Applications (NDAs) and Biologics License Applications (BLAs), elucidating the pivotal regulatory procedures imperative for pharmaceutical companies seeking approval for novel drugs and biologics. Its primary objective is to equip participants with the requisite knowledge and resources essential for navigating the intricate […]
-
Bringing In Vitro Diagnostics to Market with Real-World Evidence
In vitro diagnostic (IVD) devices are a unique type of medical device. Although they meet the definition of a medical device, they are not intended to treat a disease or condition. Rather, they are the instruments or reagents that analyze samples taken from patients. IVDs are less invasive than traditional medical devices, but still present […]
-
Preparing Now for FDA’s START Program for Rare Disease Drug Developers
On September 29, 2023, the U.S. Food and Drug Administration (FDA) took action to help further accelerate the development of novel drug and biological products for rare diseases. The action, an announcement of an opportunity for a limited number of sponsors to participate in a pilot program (Support for Clinical Trials Advancing Rare Disease Therapeutics […]
